Testosterone and prostate health: what the evidence can show

A PSA change, a urinary symptom and a prostate cancer diagnosis are different outcomes. The evidence is clearest when those questions stay separate.

Doctor consults with patient via video call. Photo: Vitaly Gariev / Unsplash.
Written by the TrunkMD editorial team
Fact checked
Updated
  1. Updated
  2. Updated
  3. Published

In carefully screened men with hypogonadism, the TRAVERSE prostate trial found no significant difference between testosterone gel and placebo in the prostate events it measured. Events were uncommon and higher-risk men were excluded, so the study does not establish lifetime safety or answer every question after prostate cancer. PSA and urinary symptoms still require appropriate assessment, with current product labeling and individual risk guiding decisions.123

Key points

  • TRAVERSE excluded men with prior prostate cancer, PSA above 3 ng/mL or severe urinary symptoms.1
  • A PSA rise is a signal for interpretation, not a cancer diagnosis by itself.2
  • FDA requested prostate/BPH labeling revisions in June 2026; the applicable product label should still be checked.4

What are the separate prostate questions?

Three questions are often collapsed into one: whether testosterone changes PSA, whether it worsens urinary symptoms, and whether it changes cancer risk. PSA is a blood marker. Lower urinary tract symptoms describe problems such as weak flow, frequency or incomplete emptying. Cancer is a diagnosis that requires a different evaluation. 1 2

A study that finds a modest PSA change does not by itself establish cancer causation. A study that finds no statistically significant cancer difference over a few years does not establish that every long-term risk is absent. These distinctions explain why evidence can be reassuring while monitoring remains appropriate.

Before therapy, a clinician considers symptoms, examination when indicated, age, family history, prior prostate findings and the patient's preferences about screening. The monitoring plan should make clear which question each test or review is intended to answer.

What did the TRAVERSE prostate trial find?

The prostate analysis included 5,204 men aged 45-80 with hypogonadism and cardiovascular disease or risk. Participants had been screened to exclude important prostate concerns. During 14,304 person-years of follow-up, high-grade prostate cancer occurred in 5 of 2,596 testosterone-treated men and 3 of 2,602 placebo-treated men. 1

The corresponding rates were 0.19% and 0.12%, with a hazard ratio of 1.62 and a wide 95% confidence interval of 0.39-6.77. The difference was not statistically significant. Other measured outcomes, including any prostate cancer, acute urinary retention, invasive procedures and new medication for urinary symptoms, also did not differ significantly. 1

Rare events make precision difficult. Eight high-grade events across both groups cannot establish that the true long-term risks are identical. The fair conclusion is that this monitored treatment strategy did not show a significant difference in those outcomes over the observed period in the selected population.

A person in a white laboratory coat looks through a microscope. Photo: Faustina Okeke / Unsplash.

Which men were not represented by that result?

TRAVERSE excluded men with a history of prostate cancer, PSA above 3 ng/mL, severe lower urinary tract symptoms or a prostate nodule or induration. Its findings therefore should not be automatically extended to someone with those features. Screening was part of the intervention context, not an incidental detail. 1

What the prostate evidence answers and leaves open
QuestionEvidence availableLimit on interpretation
Cancer events during monitored replacementRandomized gel-versus-placebo comparison in screened men. 1Uncommon events and finite follow-up do not establish lifetime equivalence.
Severe urinary symptomsThese men were excluded from TRAVERSE. 1The study cannot show that initiating therapy in that group is harmless.
Treatment after prostate cancerPrior prostate cancer was excluded. 1Requires separate evidence and specialist judgment.
PSA monitoringGuidelines describe baseline assessment and confirmed-change referral criteria. 2A threshold is a referral aid, not a cancer diagnosis.
Current product restrictionsFDA requested label revisions in 2026. 4A requested change does not prove every posted label already reflects it.

This map helps avoid both overstatement and needless alarm. A man resembling the trial population has relevant randomized evidence to discuss. A man outside that population needs an explanation of the evidence gap and how it affects his own decision.

Why can PSA increase during testosterone treatment?

Prostate tissue responds to androgens, and PSA may rise after testosterone is restored. Other causes of PSA variation also need consideration, which is why an unexpected result is interpreted and often confirmed rather than treated as proof of cancer. The Endocrine Society recommends urological consultation for specific confirmed changes during the first treatment year. 2

Its 2018 guideline identifies a confirmed increase greater than 1.4 ng/mL above baseline, a confirmed PSA above 4 ng/mL, or an abnormal examination as reasons for consultation in the monitoring context. Those are guideline referral criteria, not universal instructions to diagnose cancer or stop every prescription after one result. 2

Record the pretreatment value, the sequence of later results and relevant medications. A trend without a baseline is less informative, and a number interpreted without its clinical context can lead to unnecessary reassurance or unnecessary alarm. The role of the prescribing clinician is to coordinate that interpretation rather than simply report that a lab flag is present.

What should new urinary symptoms mean during therapy?

New urinary symptoms deserve assessment whether or not testosterone is the cause. Trouble starting urination, worsening flow, nighttime frequency or a sense of incomplete emptying can affect quality of life and may require evaluation beyond a hormone panel. The October 2025 gel label directs monitoring for worsening BPH symptoms. 5

The TRAVERSE result is helpful because several urinary outcomes did not differ significantly in screened participants. However, severe symptoms were excluded at entry. That limits the inference for someone who already has substantial obstruction or develops a major change. 1

An inability to pass urine, especially with lower abdominal pain, requires urgent clinical care. For less acute changes, bring the symptom history and medication list to the clinician. Raising or lowering testosterone simply to see whether urination changes can delay identifying the underlying cause.

A clinician in a white coat speaks with another person across a desk. Photo: Vitaly Gariev / Unsplash.

What changed in FDA prostate labeling in 2026?

FDA's current testosterone information page states that the agency requested revisions to prostate cancer and benign prostatic hyperplasia safety information in June 2026. It also requested removal of an age-related limitation-of-use statement. This is an agency update about requested labeling changes, not proof that all current package information contains identical wording. 4

The October 2025 prescribing information for AndroGel 1.62% still contains its existing prostate-related contraindication and warnings. That date difference matters. The prescriber should use the latest applicable product information and current evidence rather than assume a class announcement has already changed a specific product's instructions. 5

The Endocrine Society's July 2026 statement continues to emphasize risk assessment and monitoring and notes that long-term prostate safety remains unestablished. Regulatory revisions and uncertainty about very long follow-up can coexist. Neither should be used to claim that prostate assessment is unnecessary. 3

What should a prostate discussion before TRT include?

A useful discussion begins with what is known about the individual: baseline PSA if appropriate, prior biopsies or cancer treatment, urinary symptoms, family history and the intended benefit of testosterone. It should then separate what the randomized evidence supports from what remains uncertain for that person. 1 2

Men with prior prostate cancer need a discussion that includes their treating urologist or oncology team. The major randomized trial discussed here cannot supply the missing answer because those men were excluded. A past diagnosis should not be quietly treated as though it were the same situation as a normal screening result. 1

Finally, connect prostate follow-up to the full treatment review. Other testosterone adverse effects and hematocrit changes remain relevant even when the prostate evaluation is reassuring. Reassurance is strongest when it matches the population, outcome and time period actually studied.

Common questions

Does a higher PSA always mean prostate cancer?

No. PSA is a marker requiring interpretation in context. A confirmed rise can prompt urological evaluation, but it is not a diagnosis by itself.2

Can TRAVERSE prove TRT is safe after prostate cancer treatment?

No. Men with a history of prostate cancer were excluded. Decisions after cancer treatment require separate evidence, the details of the cancer and specialist input.1

Does every man need the same prostate testing schedule?

No. Age, baseline risk, symptoms, prior findings and preferences about screening affect the plan. Guidelines describe shared decisions about monitoring rather than one universal schedule for every adult.23

References

  1. 1.Bhasin S, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Network Open. 2023.
  2. 2.Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018.
  3. 3.Endocrine Society. Statement on Testosterone Replacement Therapy. July 16, 2026.
  4. 4.FDA. Testosterone Information. Current page accessed October 5, 2026.
  5. 5.ASCEND Therapeutics. AndroGel 1.62% prescribing information. DailyMed, revised October 2025.

This article is for general education, not medical advice, diagnosis or a treatment recommendation. A licensed clinician can interpret the evidence in the context of your symptoms, tests, medicines and fertility plans.